“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions”—Treatment of ALL

The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits.

Source: Clinical Lymphoma, Myeloma and Leukemia - April 2, 2018 Category: Hematology Authors: Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer Tags: SOHO State of the Art Updates and Next Questions Source Type: research